JPMorgan lowered the firm’s price target on AnaptysBio (ANAB) to $36 from $66 and keeps an Overweight rating on the shares. The firm says sentiment on AnaptysBio shares is “clearly negative” post the ANB032 failure and discontinuation in atopic dermatitis and Lilly’s peresolimab discontinuation. Street expectations for the Phase 2 rosnilimab rheumatoid arthritis update are clearly low, with the shares trading incrementally ahead of cash, the analyst tells investors in a research note. JPMorgan sees a win scenario as ACR50 being ahead of IL-6 therapy and more line with JAK treatment with a clean safety profile.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio price target lowered to $20 from $30 at Truist
- Broadcom tops $1T market cap on AI enthusiasm: Morning Buzz
- Biotech Alert: Searches spiking for these stocks today
- Adobe outlook disappoints, Kroger announces $7.5B buyback: Morning Buzz
- AnaptysBio price target lowered to $36 from $90 at Guggenheim